Navigation Links
Lower contrast agent dose feasible in 320 row CT angiography
Date:9/30/2011

The analysis of 180 CT angiography studies done using a 320 detector row CT scanner found that a contrast media protocol based on 60 milliliters of iopamidol "had sufficient enhancement in more than 96% of coronary segments," said Frank Rybicki, MD, of Brigham and Women's Hospital in Boston, and one of the authors of the study.

"Many centers currently use a higher iodine load comparable or equal to 80 milliliters of iopamidol," he said. The study shows that "this is not necessary, and the extra contrast means unnecessary costs and increased risk of contrast-induced nephropathy (CIN) to the patients." The risk of CIN is of special concern for these patients because they commonly have a renal insufficiency, which is known major risk factor for CIN, Dr. Rybicki added.

"We analyzed larger patients only (those with a body mass index of more than 30) and found that 92% of coronary segments had sufficient enhancement," said Dr. Rybicki. "These results support the general use of 60 milliliters of iopamidol for CT angiography done on 320 detector row CT scanners," he said.


'/>"/>

Contact: Keri Sperry
ksperry@arrs.org
703-858-4315
American Roentgen Ray Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Cancer screening rates lower among those with fatalistic attitudes
2. Liver cancer incidence lower in patients with nonalcoholic fatty liver disease than hepatitis C
3. Lots of Coffee Might Lower Depression Risk: Study
4. Study to test efficacy of prenatal intervention, support on lowering postpartum depression in teens
5. Liposuction May Lower Certain Blood Fats, Researcher Says
6. IUDs May Lower Womens Risk for Cervical Cancer: Study
7. Study finds hospitals of last resort deliver lower quality of lung cancer care
8. Big Health Plans Can Negotiate Lower Hospital Costs: Study
9. Consolidation of health plans may help lower hospital costs, study finds
10. Alzheimers brains found to have lower levels of key protein
11. Could Lots of Chocolate Lower Your Heart Risk?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: